Takeda Reports U.S. Trial Data Showing Success For Bowel Disease Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said two U.S. clinical trials have shown its vedolizumab drug for treating inflammatory bowel diseases is effective for treating a potential 1.4 million patients.